Immunotherapy

The journalist Jamie Reno just published "My Two-Decade Journey with Cancer Immunotherapy" on Healthline.

If you've never read his work before, you should be aware of it.

He writes on a lot of topics, but the one I like most is his work on cancer, especially lymphoma. He is, after all, a 21 year survivor of Follicular Lymphoma. (It's always great to read about the experiences of people who have survived so long.)

He talks about this in the Healthline article, especially his experience with Immunotherapy. In particular, he's had Bexxar, the RadioImmunoTherapy I wrote about in my last post. He had 12 years of Progression Free Survival with RIT.

The article talks about more than just his experience. It's a nice overview of Immunotherapy, especially for blood cancer. (He's as excited about CAR-T as the rest of us.) It's as clear an explanation of Immunotherapy, and why it will play such a big role in our futures, as you'll find online.

Reno is also the author of the book Hope Begins in the Dark, which tells the stories of 40 Lymphoma survivors. An excellent read if you're looking to see what some other Lymphoma journeys have looked like.

One more recent piece by Reno: on his blog, about a month ago, a discussion of some of the Lymphoma treatments recently approved by the FDA. (I've had this on my list of things to share with you since I saw it; this is a good excuse to get it to you).

In his usual clear prose, he discusses the treatments Aliqopa, a kinase inhibitor (I've written about this under its other name, Copanlisib); Gazyva, also known as Obinutuzumab, a monoclonal antibody like Rituxan; Yescarta, the CAR-T therapy; liso-cel, another CAR-T therapy; and some other trends in Lymphoma genetic-based treatments.

All good stuff. As I said, his writing on cancer is mu favorite, but if you like what you see, browse his blog (linked above) and see what else he has to say on a variety of topics.

Enjoy.